Press releases and corporate news

Informationsmöte den 11/4

  • -

Tisdagen den 11 april arrangerade PEPTONIC medical ett informationsmöte med aktieägarna. På mötet berättade styrelse och ledning om den nyss slutförda fas IIb-studien och om planerna framåt. Här nedan presenteras svar på

Read More

Road show calendar of PEPTONIC medical

  • -

PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO) on Aktietorget Stock Exchange (Stockholm)

Read More

PEPTONIC medical raises SEK 6.9 million

  • -

PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement, the number of shareholders in

Read More

Last patient completed VAGITOCIN® PK study

  • -

PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician in accordance with the study

Read More

Meeting with MPA

  • -

A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13. The results from the recently concluded clinical study and the design of the planned phase III were

Read More

Approval of patent

  • -

A new formulation patent for oxytocin was approved by the Swedish patent authorities in February 2013. PEPTONIC has received a patent on the new formulation of Vagitocin. Sweden was the

Read More

PEPTONIC has raised 13.6 MSEK

  • -

PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This constituted the possibilities for PEPTONIC

Read More

All press releases on Spotlightstockmarket.com

All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

Contact us

Please contact us if you would like to know more about PEPTONIC medical or Vagivital™.

Contacts »